MT Newswires Live11:36
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) obtained approval from China's National Medical Products Administration for phase Ib/II clinical trials of HLX701, according to a Wednesday filing on the Shanghai bourse.
The drug will be tested within the mainland in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
